FLT3 and acute myeloid leukemia: In combination with intensive chemotherapy, in April 2017, it was approved by the US FDA for the frontline treatment of adult patients with newly diagnosed FLT3-mutated AML, at the same time being the first drug to receive regulatory approval for AML treatment in the US since the year 2000 [67].